DCAT Research & Benchmarking
DCAT Research & Benchmarking
DCAT’s 2023 Study:
Envisioning Bio/Pharma Sourcing and Supply Chain Management in 2030
Sourcing, procurement, and supply-chain operations are traditionally expected to focus on cost-of-goods and inventories. However, the pandemic and other economic and geopolitical events have highlighted vulnerabilities in bio/pharma supply arrangements and added sustainability as a critical objective. As a result, sourcing and supply-chain management has become more complex and critical, requiring a broader range of skills and capabilities than in the past.
To help DCAT Member Companies understand how the sourcing and supply-chain management function is evolving and where it is heading, the DCAT Research and Benchmarking Committee conducted a study, Envisioning Bio/Pharma Sourcing and Supply Chain Management in 2030, based on a series of interviews with senior executives from DCAT Member Companies (both bio/pharma companies and suppliers)
Is your company keeping pace with change?
Gain executive views on their vision for the supply-chain organization of the future: what bio/pharma sourcing and supply-chain functions will look like, how suppliers can prepare for changing customer expectations, and how the role of suppliers will evolve.
Key findings from the report examine:
- Strategic drivers of change in sourcing and supply-chain management
- The criticality of supply risk management and strategies taken to further mitigate risk
- Network integration: internal and external manufacturing networks
- Sustainability and environmental, social and governance: goals and expectations among bio/pharma customers and suppliers
- Organizational and individual skill sets needed now and in the future.
The report summarizes the most important initiatives cited by procurement and supply-chain executives and where the industry stands in implementing these initiatives: a valuable resource that companies can use to benchmark their own progress in reshaping their sourcing and supply-chain strategies and operations.
About DCAT Research & Benchmarking
DCAT Research & Benchmarking is a complimentary, value-added member benefit providing in-depth studies that examine the crucial issues impacting the bio/pharmaceutical manufacturing value chain and the bio/pharma customer—supplier relationship. DCAT Research & Benchmarking studies are developed by the DCAT Research & Benchmarking Committee, composed of member representatives with diverse industry experience, to identify the topics of greatest interest for DCAT member companies and is administered and prepared using an external research firm.
DCAT Research & Benchmarking Report Archives
Incorporating Sustainability in the Bio/Pharmaceutical Supply Chain (2022)
Examines the driving factors surrounding sustainability and the progress being made toward sustainability in the supply chain (including manufacturing, packaging, and logistics) in the bio/pharma industry. Download the report here.
For reports prior to 2022, contact Jessica Dunkerly, DCAT Project Specialist, email@example.com or +1.856.388.2965. See reports below.
Managing Business Continuity Risks (2021)
Details how Bio/pharmaceutical companies and suppliers are managing business continuity risks resulting from the COVID-19 pandemic and how lessons learned are affecting their approach to supply-risk management overall.
Managing Bio/Pharma Supply Chains in an Uncertain Global Trade Environment (2020)
Provides insights on whether bio/pharma companies and their suppliers believe the deteriorating trade environment is a major threat, and what they are doing to confront the real and potential risks to their supply chains.
Examining the Current and Future Alignment of the Pharma Customer—Supplier Relationship (2019)
Evaluates the current and near-future imperatives for both pharma customers and suppliers, highlighting areas of alignment and misalignment and the opportunities for improvement.
Value-Based Metrics: Examining the Pharma Customer—Supplier Relationship (2018)
Examines the practices and key metrics used by both pharma companies and suppliers to measure the benefits of value-creation activities in the supply of direct materials.
Value Creation in Pharmaceutical Procurement (2017)
Surveying the CPOs of large to mid-sized pharma companies, the study examines Procurement’s role internally and with suppliers to deliver value for achieving corporate and business goals.